Gilead Sciences Buys Liver-Drug Program
Gilead Sciences Inc. said it would acquire a liver-drug program from Nimbus Therapeutics LLC for an upfront payment of $400 million and up to $800 million if certain milestone payments are reached. Gilead is buying Nimbus Apollo Inc., a subsidiary of Nimbus Therapeutics, and its Acetyl-CoA Carboxylase inhibitor program. The inhibitors are currently being tested to treat nonalcoholic steatohepatitis, a disease caused by a buildup of...>> view originalUPDATE 1-US to raise payments to insurers for Medicare Advantage 2017 plans
(Adds change to drug plan payments)NEW YORK, April 4 U.S. health insurers that provide Medicare Advantage plans to elderly and disabled Americans will receive government payments in 2017 that are 0.85 percent higher on average than in 2016, reflecting small anticipated growth in medical costs, the U.S. Department of Health and Human Services said on Monday.Health and Human Services' final plan to raise payments is a bit lower than the 1.35 percent increase the agency had proposed in February. ..>> view originalLab-grown skin shows promise as better option for burn victims
TOKYO, April 4 (UPI) -- Scientists in Japan have grown skin that has hair follicles and sweat glands, which they say could lead to better functioning skin for burn victims. The skin, grown with cells taken from a mouse's gums, was implanted in a mouse and integrated well, suggesting a grafting technique superior to other standard methods, the scientists report in a study published in the journal Science Advances. In addition to creating skin with the working biological components of skin, the s..>> view originalExclusive: Makers took big price increases on widely used US drugs
NEW YORK Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found.Prices for four of the nation's top 10 drugs increased more than 100 percent since 2011, Reuters found. Six others went up more than 50 percent. Together, the price increases on drugs for arthritis, high cholesterol, asthma and other common problems added billions in costs for co..>> view originalOnce-promising cholesterol drug fails to improve patients' heart health
Despite its success in lowering LDL -- known as "bad" cholesterol -- while increasing levels of "good" cholesterol HDL, the drug evacetrapib is not effective in helping protect patients from major cardiovascular events like heart attack and stroke, a large clinical trial finds.The research, presented at the American College of Cardiology's 65th Annual Scientific Session on Sunday, explains why the drug's maker, Eli Lilly, halted the study in October. "Here we've got an agent that more than doub..>> view originalSome 'Wylwood' Frozen Broccoli Cuts Voluntarily Recalled Over Listeria Fears
A brand of packaged frozen broccoli sold in 11 states is being voluntarily recalled over concerns it could be contaminated with a dangerous bacteria, according to the company. The Alimentos Congelados, S.A. (Pinula) is recalling 1,800 cases of its ...>> view original
Monday, April 4, 2016
Gilead Sciences Buys Liver-Drug Program and other top stories.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment